Mingjuan Li

Mingjuan Li

Auto-generated profile, based on publicly available information

Mingjuan Li

Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2014 in Molecular Breeding
Verified
Journal Article
Closed access
PDF file
GXGuoyun Xu
Guoyun Xu
YCYanchun Cui
Yanchun Cui
MWManling Wang
Manling Wang
MLMingjuan Li
Mingjuan Li
XYXuming Yin
Xuming Yin
XXXinjie Xia
Xinjie Xia

1 July 2023 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
JLJiecheng Lin
Jiecheng Lin
Na HuangNa Huang
Na Huang
MLMingjuan Li
Mingjuan Li
MZMengyuan Zheng
Mengyuan Zheng
ZWZhuoxiang Wang
Zhuoxiang Wang
BDbaoyue ding
baoyue ding
Purpose: Malignant melanoma (MM), the most lethal skin cancer, is highly invasive and metastatic. These qualities are related to not only genetic mutations in MM itself but also the interaction of MM cells with the immune system and microenvironment. This study aimed to construct a combined immunotherapy and gene therapy drug delivery system for the effective treatment of MM. Methods: Mature dendritic cell (mDC) exosomes (mDexos) with immune induction functions were used as carriers. BRAF siRNA (siBRAF) with the ability to silence mutated BRAF in MM was encapsulated in mDexos by electroporation to construct a biomimetic nanosystem for the codelivery of immunotherapy and gene therapy drugs (siBRAF-mDexos) to the MM microenvironment. Then, we investigated the nanosystem’s serum stability and biocompatibility, uptake efficiency in mouse melanoma cells (B16-F10 cells), cytotoxicity against B16-F10 cells and inhibitory effect on BRAF expression. Furthermore, we evaluated its antimelanoma activity and safety in vivo. Results: SiBRAF-mDexos were nanosized. Compared to siBRAF, siBRAF-mDexos displayed significantly increased serum stability, biocompatibility, uptake efficiency in B16-F10 cells, and cytotoxicity to B16-F10 melanoma cells; they also had a significantly greater inhibitory effect on BRAF expression and induced T-lymphocyte proliferation. Moreover, compared with siBRAF, siBRAF-mDexos showed significantly enhanced anti-MM activity and a high level of safety in vivo. Conclusion: The study suggests that the siBRAF-mDexo biomimetic drug codelivery system can be used to effectively treat MM, which provides a new strategy for combined gene therapy and immunotherapy for MM.

1 February 2010 in The Journal of Physical Chemistry C
Verified
Journal Article
Closed access
LSLi-Qun Sun
Li-Qun Sun
MLMing-Juan Li
Ming-Juan Li
RCRui-Hui Cui
Rui-Hui Cui
HXHaiming Xie
Haiming Xie
RWRong-Shun Wang
Rong-Shun Wang

9 June 2012 in Journal of Solid State Electrochemistry
Verified
Journal Article
Closed access
PDF file
MLMingjuan Li
Mingjuan Li
LSLiqun Sun
Liqun Sun
Kai SunKai Sun
Kai Sun
SYShihua Yu
Shihua Yu
RWRongshun Wang
Rongshun Wang
HXHaiming Xie
Haiming Xie

20 January 2024 in Asian Journal of Surgery
Verified
Journal Article
Open access
MLMingjuan Li
Mingjuan Li
JYJingfu Yu
Jingfu Yu
ZGZhaoliang Gu
Zhaoliang Gu
ALAi-jie Liu
Ai-jie Liu